Last reviewed · How we verify
ID-085
At a glance
| Generic name | ID-085 |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease (PHASE1)
- A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ID-085 CI brief — competitive landscape report
- ID-085 updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Ltd. portfolio CI